Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study.
chronic infection
direct-acting antiviral agents (DAA)
hemodialysis
hepatitis C infection (HCV)
kidney transplantation
liver fibrosis
occult hepatitis C infection
treatment efficacy
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
17 May 2023
17 May 2023
Historique:
received:
04
05
2023
accepted:
15
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
The chronic kidney disease (CKD) population, including kidney transplant recipients (KTRs) and subjects on renal replacement therapy, is particularly vulnerable to unfavorable outcomes from chronic hepatitis C (CHC). Currently, there are oral direct-acting antiviral agents (DAAs) available to eradicate the virus with favorable short-term outcomes; however, their long-term effects are lacking. The aim of the study is to assess the long-term efficacy and safety of DAA therapy in the CKD population. An observational, cohort single-center study was performed. Fifty-nine CHC subjects with CKD, treated with DAAs between 2016 and 2018, were enrolled in the study. Safety and efficacy profiles were assessed, including sustained virologic response (SVR), occult hepatitis C infection (OCI) incidence, and liver fibrosis. SVR was achieved in 96% of cases (n = 57). OCI was diagnosed only in one subject following SVR. Significant liver stiffness regression was observed 4 years after SVR compared to baseline values (Mdn = 6.1 kPa, IQR = 3.75 kPa; 4.9 kPa, IQR = 2.9 kPa), DAAs provide a safe and effective cure for CHC in both CKD patients and KTRs with a favorable safety profile in the long-term follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
The chronic kidney disease (CKD) population, including kidney transplant recipients (KTRs) and subjects on renal replacement therapy, is particularly vulnerable to unfavorable outcomes from chronic hepatitis C (CHC). Currently, there are oral direct-acting antiviral agents (DAAs) available to eradicate the virus with favorable short-term outcomes; however, their long-term effects are lacking. The aim of the study is to assess the long-term efficacy and safety of DAA therapy in the CKD population.
METHODS
METHODS
An observational, cohort single-center study was performed. Fifty-nine CHC subjects with CKD, treated with DAAs between 2016 and 2018, were enrolled in the study. Safety and efficacy profiles were assessed, including sustained virologic response (SVR), occult hepatitis C infection (OCI) incidence, and liver fibrosis.
RESULTS
RESULTS
SVR was achieved in 96% of cases (n = 57). OCI was diagnosed only in one subject following SVR. Significant liver stiffness regression was observed 4 years after SVR compared to baseline values (Mdn = 6.1 kPa, IQR = 3.75 kPa; 4.9 kPa, IQR = 2.9 kPa),
CONCLUSION
CONCLUSIONS
DAAs provide a safe and effective cure for CHC in both CKD patients and KTRs with a favorable safety profile in the long-term follow-up.
Identifiants
pubmed: 37240622
pii: jcm12103513
doi: 10.3390/jcm12103513
pmc: PMC10219487
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2015 Oct 17;386(10003):1537-45
pubmed: 26456905
Int J Artif Organs. 2009 Aug;32(8):473-81
pubmed: 19844890
J Hepatol. 2020 May;72(5):839-846
pubmed: 31790766
Clin Infect Dis. 2013 Jul;57(2):240-6
pubmed: 23592832
J Viral Hepat. 2014 Dec;21(12):930-7
pubmed: 24472062
Cancers (Basel). 2021 Jul 22;13(15):
pubmed: 34359594
Kidney Int. 2022 Dec;102(6S):S129-S205
pubmed: 36410841
BMC Gastroenterol. 2019 Apr 27;19(1):63
pubmed: 31029101
Gastroenterology. 2005 Feb;128(2):343-50
pubmed: 15685546
N Engl J Med. 2017 Oct 12;377(15):1448-1455
pubmed: 29020583
Am J Transplant. 2021 Aug;21(8):2824-2832
pubmed: 33346917
Scand J Gastroenterol. 2009;44(12):1487-90
pubmed: 19900055
J Med Virol. 2010 Sep;82(9):1554-9
pubmed: 20648609
Nat Rev Nephrol. 2019 Feb;15(2):73-86
pubmed: 30455426
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
J Hepatol. 2017 Dec;67(6):1204-1212
pubmed: 28802876
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Am J Transplant. 2016 May;16(5):1588-95
pubmed: 26604182
J Viral Hepat. 2007 Jan;14(1):36-40
pubmed: 17212642
Sci Rep. 2021 Jun 3;11(1):11681
pubmed: 34083617
Clin Drug Investig. 2017 Nov;37(11):1009-1023
pubmed: 28871475
Hepatology. 2020 Feb;71(2):686-721
pubmed: 31816111
Clin J Am Soc Nephrol. 2012 Apr;7(4):549-57
pubmed: 22403269
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
Clin Gastroenterol Hepatol. 2017 Jan;15(1):132-136
pubmed: 27392759
Liver Int. 2016 Jun;36(6):807-16
pubmed: 26923436
J Formos Med Assoc. 2021 May;120(5):1259-1268
pubmed: 33339709
J Infect Dis. 2004 Jan 1;189(1):7-14
pubmed: 14702147
J Clin Transl Hepatol. 2018 Mar 28;6(1):79-84
pubmed: 29607308
J Hepatol. 2016 Apr;64(4):773-80
pubmed: 26626497
J Gastroenterol Hepatol. 2018 Apr;33(4):942-949
pubmed: 28976021
Clin Gastroenterol Hepatol. 2016 Jan;14(1):124-31.e1
pubmed: 26196445
Gastroenterology. 1994 Aug;107(2):492-8
pubmed: 7518783
J Clin Med. 2021 Aug 31;10(17):
pubmed: 34501398
PLoS One. 2015 Sep 21;10(9):e0138522
pubmed: 26390404
Kidney Int. 2004 Jun;65(6):2335-42
pubmed: 15149347
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
J Clin Pharm Ther. 2018 Oct;43(5):707-713
pubmed: 29737025
Ann Gastroenterol. 2021;34(3):438-446
pubmed: 33948071
Gastroenterology. 2019 Nov;157(5):1264-1278.e4
pubmed: 31356807
J Hepatol. 2016 Oct;65(4):856-858
pubmed: 27318327
World J Hepatol. 2022 Jun 27;14(6):1120-1130
pubmed: 35978676
Dig Dis Sci. 2015 Dec;60(12):3801-13
pubmed: 26195311
Antivir Ther. 2010;15(3):281-91
pubmed: 20516548
EBioMedicine. 2019 Aug;46:227-235
pubmed: 31345785
J Med Virol. 2009 Jul;81(7):1198-203
pubmed: 19475603
Medicine (Baltimore). 2020 May 29;99(22):e20436
pubmed: 32481445
J Clin Transl Hepatol. 2018 Jun 28;6(2):155-160
pubmed: 29951360
J Hepatol. 2013 May;58(5):1028-41
pubmed: 23262248
Eur J Gastroenterol Hepatol. 2019 Apr;31(4):506-513
pubmed: 30461522
Aliment Pharmacol Ther. 2022 May;55(9):1169-1178
pubmed: 35235245
Gastroenterol Res Pract. 2015;2015:579147
pubmed: 26221136
Ann Hepatol. 2018 Apr 9;17(3):364-391
pubmed: 29735788
Kidney Int. 2020 Jan;97(1):193-201
pubmed: 31337501
Clin Gastroenterol Hepatol. 2018 Jan;16(1):27-38.e4
pubmed: 28479504
J Viral Hepat. 2012 Sep;19(9):601-7
pubmed: 22863263
Hepatology. 2009 Feb;49(2):665-75
pubmed: 19105211
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Am J Transplant. 2014 Feb;14(2):272-83
pubmed: 24472190
Clin Gastroenterol Hepatol. 2022 May;20(5):1151-1162.e6
pubmed: 34333150